Portal to the Penn Neuroscience Community
Home
MINS Members
MINS News
Weekly Events
MINS Colloquium Schedule
History
Community Outreach Programs
Neuroscience Graduate Group
Other Educational Activities
Society for Neuroscience
Classified Ads
MINS Members
John Q. Trojanowski, M.D., Ph.D.
Co-Director, Center for Neurodegenerative
Disease Research
Director, Institute on Aging & Director, Alzheimer's Disease
Core Center
William Maul Measey-Truman G. Schnabel, Jr. MD Professor of Geriatric Medicine and Gerontology
Department of Pathology and Laboratory Medicine
HUP, Maloney 3rd Floor, 36th and Spruce Streets
Philadelphia, PA 19104-4283 USA
Tel: 215-662-6399; Fax: 215-349-5909
E-mail: trojanow@mail.med.upenn.edu
CNDR Website: http://www.uphs.upenn.edu/cndr/
IOA Website: http://www.med.upenn.edu/aging
ADCC Website: http://www.med.upenn.edu/ADC
Click here for selected publications since Dr. Trojanowski's arrival at Penn
RESEARCH INTERESTS
Neurodegenerative diseases caused by filamentous aggregates of A-beta, tau and alpha-synuclein as well as in vitro and animal models of these diseases.RESEARCH TECHNIQUES
Morphological, genetic, molecular biological and biochemical methods are used to study samples from patients with neurodegenerative diseases as well as those from model systems.RESEARCH SUMMARY
Research currently centers on molecular mechanisms of neuron dysfunction, degeneration and death in normal aging and in neurodegenerative diseases (Alzheimer's and Parkinson's disease, frontotemporal dementias with/without parkinsonism, motor neuron disease, etc.). This research uses immunological, biochemical, genetic, molecular and morphological methods to study human CNS and PNS tissue samples (postmortem or surgical), cell lines, synthetic proteins, and transgenic models of neurodegenerative diseases. Dr. Trojanowski is involved in collaborative initiatives between PENN Medicine and the University of Pennsylvania School of Nursing to advance drug discovery, clinical research, and patient care related to Alzheimer's disease and the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test whether serial magnetic resonance imaging, positron emission tomography, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease.
